EnteroMedics (ETRM) Reports In-Line Q2 EPS

Go back to EnteroMedics (ETRM) Reports In-Line Q2 EPS

EnteroMedics Reports Second Quarter 2015 Financial Results

August 6, 2015 7:01 AM UTC

ST. PAUL, Minn., Aug. 6, 2015 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three and six months ended June 30, 2015.

For the three months ended June 30, 2015, the Company reported its first U.S. sales of $79,000 with gross profits totaling $48,000.  The Company reported a net loss of $7.4 million, or $0.10 per share, including selling, general and administrative expenses of $4.9 million and research and development expenses of $2.5 million. For the six months ended June... More